Mind the Byte–Prosilico: drug discovery + development software, 201711– collab co-promotion + product integration

	Period	2017-11-15
	Partner, 1st	Mind the Byte S.L.
	Group	Mind the Byte (Group)
	Partner, 2nd	Prosilico (SE)

Mind the Byte S.L.. (11/15/17). "Press Release: Mind the Byte and Prosilico Sign a Strategic Partnership Agreement".

> Together, the two companies will provide a broad portfolio of in silico models covering most aspects of virtual drug discovery and development.

> Prosilico software will now be included in Mind the Byte’s SaaS platform and both firms will promote each other’s technologies.

> This agreement fits with Mind the Byte’s plans to expand internationally through strategic alliances and increase its range of services.

Mind the Byte, a bioinformatics company located at the Barcelona Science Park (PCB) and at Copenhagen BioScience Park (COBIS), announces that it has just signed an agreement to share technology with the Swedish-based company Prosilico. Within this partnership, Mind the Byte adds to its in silico drug discovery platform the capacity of doing some virtual predictions of human clinical ADME/PK and covers now a wider range of expertise and know-how.

The platform, which uses Cloud Computing, already allows studying the mechanism of action of drugs and conducting computational screenings for hit finding or drug repurposing. Now, it will be complemented with some Prosilico tools to predict relevant human in vivo ADME/PK properties in models independently validated by pharma companies.

The CEO of Mind the Byte Alfons Nonell-Canals says, “We have selected Prosilico as a partner because they have been able to utilize human clinical data to develop predictive models covering a wide range of ADME/PK applications and diminishing a lot of the otherwise common in vitro and in vivo experiments.”

“Prosilico founding partners have documented their innovative work by a number of publications over the years and they bring a long big pharma experience from AstraZenca which makes Prosilico a very attractive partner for us,” says Thomas Högberg, Chief Strategic Officer also from Mind the Byte.

On the other side, the CEO of Prosilico, Urban Fagerholm, concludes, “Mind the Byte is at the forefront of computational drug discovery providing a unique Software as a Service platform allowing also midsize pharma, biotechs and institutions an affordable and flexible access to High Performance Computing. We hope that being on this platform will advance the use of our human-based in silico ADME/PK tools and we look forward to the collaboration.”

About Mind the Byte

Mind the Byte is a bioinformatics company that develops and provides software for computational drug discovery using Big Data and Machine Learning (AI) approaches. The company works with partners on a consultancy basis or offers an easy to use Software as a Service (SaaS) package to allow clients to apply the High-performance computing platform on a flexible pay-per-use basis without investment in hardware or software licenses. Mind the Byte is an Amazon Web Services technology partner to ensure security and reliability. The company was founded in 2011 by Alfons Nonell-Canals and is located at the Barcelona Science Park and Copenhagen Bio Science Park.

About Prosilico

Prosilico has developed a unique platform for predictions of human in vivo ADME/PK, doses and exposures direct from molecular structure shown to outperform currently used in vitro and animal in vivo based methods in accuracy and range. The company also provides services and their models are also applicable for prodrugs, metabolites and various kinds of chemicals. This Swedish company was founded in July 2014 by ex-AstraZeneca pharmacokineticist Urban Fagerholm, associate professor in biopharmaceutics/pharmacokinetics at Uppsala University. Head of data analysis, doctor and computational chemist Sven Hellberg joined the company in 2016.